Rectal fistulas after prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 1, 2005, Pages 150-154

  Tran, Audrey ^a   Wallner, Kent ^a,b,c,e   Merrick, Gregory ^d   Seeberger, Jergen ^c   Armstrong, Julius ^a   Mueller, Amy ^a   Cavanagh, William ^a,b   Lin, Daniel ^a,b   Butler, Wayne ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Puget Sound Health Care System   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d WHEELING HOSPITAL   (United States)

^e Department of Radiation Oncology ^*  (United States)

Author keywords

Brachytherapy; Morbidity; Prostate carcinoma; Rectum

Indexed keywords

COMPUTERIZED TOMOGRAPHY; IMPLANTS (SURGICAL); MEDICAL IMAGING; ONCOLOGY; PATIENT MONITORING; TOXICITY; TUMORS;

BRACHYTHERAPY; MORBIDITY; PROSTATE CARCINOMA; RECTUM;

RADIOTHERAPY;

IODINE 125; PALLADIUM 103; PALLADIUM; RADIOACTIVE IODINE; RADIOISOTOPE;

ADULT; AGED; ARGON PLASMA COAGULATION; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CLINICAL TRIAL; COLOSTOMY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOSCOPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUESTIONNAIRE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECTUM BIOPSY; RECTUM FISTULA; RECTUM HEMORRHAGE; TOXICITY; ANALYSIS OF VARIANCE; CASE REPORT; GASTROINTESTINAL HEMORRHAGE; MIDDLE AGED; MULTICENTER STUDY; PROSTATE TUMOR; RECTUM DISEASE;

AGED; ANALYSIS OF VARIANCE; BRACHYTHERAPY; GASTROINTESTINAL HEMORRHAGE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PALLADIUM; PROSTATIC NEOPLASMS; RADIOISOTOPES; RECTAL DISEASES; RECTAL FISTULA;

EID: 26944477062     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.01.021     Document Type: Article

References (23)

1. Snyder KM, Stock RG, Hong SM, et al. Defining the risk of developing grade 2 proctitis following 125-1 prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50:335-341.
2. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:119-124.
3. 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;55:342-353.
4. Mueller A, Wallner K, Merrick G, et al. Peri-rectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. Int J Radiat Oncol Biol Phys 2004;59:1047-1052.
5. Merrick GS, Butler WM, Wallner K, et al. Late rectal function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;57:42-48.
6. Howard A, Wallner K, Han B, et al. Clinical course and dosimetry of rectal fistulas after prostate brachytherapy. J Brachyther Int 2001;17:37-42.
7. Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostatourethral-rectal fistula after prostate brachytherapy: Incidence and risk factors. Cancer 2000;89:2085-2091.
8. Wallner K, Merrick G, True L, et al. I-125 versus Pd-103 for low risk prostate cancer: Morbidity outcomes from a prospective randomized multicenter trial. Cancer J Sei Am 2002;8:67-73.
9. Ghaly M, Wallner K, Merrick G, et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: Morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys 2003;55: 1288-1293.
10. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Techn Urol 2000;6:78-84.
11. Badiozamani KR, Wallner KE, Cavanagh W, et al. Comparability of CT-based and TRUS-based prostate volumes. Int J Radiat Oncol Biol Phys 1999;43:375-378.
12. Hilts M, Spandinger I, Keyes M. Comparison of methods for calculating rectal dose after 125-I prostate brachytherapy implants. Int J Radiat Oncol Biol Phys 2002;53:775-785.
13. Sheretz T, Wallner K, Merrick G, et al. Factors predictive of rectal bleeding after Pd-103 and supplemental beam radiation for prostate cancer. Brachytherapy 2004;3:130-135.
14. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-1957.
15. Elliott K, Wallner K, Merrick G, et al. Medical malpractice of prostate brachytherapy. Brachytherapy. 2004;3:231-236.
16. Moreira S, Seigne J, Ordorica R, et al. Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma. Br J Urol 2004;93:31-35.
17. Jordan GH, Lynch DF, Warden SS, et al. Major pelvic complications following interstitial implantation of iodine-125 for carcinoma of the prostate. J Urol 1985;134:1212-1214.
18. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001;50:605-614.
19. Stock RG, Stone NN, Dahlal M, et al. What is the optimal dose for 125-I prostate implant? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term symptoms. Brachytherapy 2002;1:83-89.
20. Smith S, Wallner K, Han B, et al. Argon plasma coagulation for rectal bleeding following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:636-642.
21. Choi S, Wallner KE, Merrick G, et al. Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer J Sci Am 2004;10:175-180.
22. 103Pd for low risk prostate cancer: Preliminary biochemical outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 2003;57:1297-1303.
23. Merrick GS, Butler WM, Wallner KE, et al. Extracapsular dose distribution following permanent prostate brachytherapy. Am J Clin Oncol 2003;26:178-189.